Finally, reflection is needed around implementation strategies at the level of the system, facility and individual healthcare workers
Phase 2 weight management: In a Phase 2 trial published in the NEJM, the highest retatrutide dose produced roughly 24% average body-weight reduction over 48 weeks the largest result reported for an incretin agonist in such a window
These solutions make a significant difference for many patients looking for effective weight management
For this, we used Trametinib, a pharmacological inhibitor targeting MEK, the upstream kinase mediating ERK phosphorylation and activation (Gilmartin et al, 2011)
Modifiable risk factors include cigarette smoking (the strongest modifiable risk factor, with smoking cessation strongly recommended), hypertension, cardiovascular disease, and potentially obesity